Chemical Biology Program

The Arvin Dar Lab


Dr. Arvin Dar
Arvin Dar, PhD

The Dar laboratory explores cancer mechanisms and new approaches in chemical biology. Our research integrates genetics, biochemistry, structure, and small molecule discovery. Our primary goal is to develop tools that enable us to modulate cell signaling networks, allowing for in-depth mechanistic exploration of disease and potential therapeutic applications.

In our previous work, we successfully designed chemical switches and conformational modulators that selectively bind to specific targets of interest. By manipulating the conformational equilibrium, we can effectively influence the formation of specific states or complexes. Another area of research has been on molecular glues that operate at the interface of biomolecular complexes to regulate the assembly, lifetime, and fate of signal transduction events.

Overall, we are focused on the development of chemical tools and probes to target cancers driven by dysregulated enzymes, receptors, cellular communication pathways, and the tumor microenvironment.

Research Projects


Rialdi A., Duffy M,  Scopton, A,  Zhao J, Schwarz M, Ruiz de Galarreta M, Lim YT, Molina-Sanchez P, Rosemann F, Khan Z, Lakshmananm M, Tan SY, Jin J, Villanueva A, Michailidis E, De Jong YP, Rice CM, Sobota RM, Lujambio A*, Guccione E*, and Dar A.C.*. A kinase inhibitor with specificity against b-catenin mutant hepatocelllular carcinoma generated through reduced anti-target engagement. Nature Cancer. 2023, In press.

View All Publications


Dr. Arvin Dar

Arvin Dar, PhD

  • Arvin Dar’s lab develops chemical tools and probes to explore disease mechanisms and the structural biology of cancer targets.
  • University of Toronto
[email protected]
Email Address
Office Phone


Yousuf Ansari

Research Scholar

Christella Gordon

Research Scholar

Satendra Gurjar

Research Scholar

Claudia Korzeniecki

Research Assistant

Lab Affiliations


  • Mark Foundation for Cancer Research ASPIRE Award
  • Friedman Brain Institute Scholar
  • Pershing Square Sohn Prize for Young Investigators (PSSCRA)
  • Pew-Stewart Scholars for Cancer Research (Pew Foundation)
  • Damon Runyon-Rachleff Innovation Award
Read more
  • NIH Director’s New Innovator Award

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Arvin Dar discloses the following relationships and financial interests:

  • Nested Therapeutics
    Equity; Intellectual Property Rights; Professional Services and Activities
  • Prometeo Therapeutics
    Equity; Intellectual Property Rights; Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures